Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry ; volume:18 ; number:1 ; day:30 ; month:3 ; year:2016 ; pages:1-8 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (30.3.2016), 1-8, 12.2016
- Creator
-
Truchetet, Marie-Elise
- Contributor
-
Poursac, Nicolas
Barnetche, Thomas
Shipley, Emilie
Gottenberg, Jacques-Eric
Bannwarth, Bernard
Richez, Christophe
Schaeverbeke, Thierry
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-0956-7
- URN
-
urn:nbn:de:1111-20160401309
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Truchetet, Marie-Elise
- Poursac, Nicolas
- Barnetche, Thomas
- Shipley, Emilie
- Gottenberg, Jacques-Eric
- Bannwarth, Bernard
- Richez, Christophe
- Schaeverbeke, Thierry
- SpringerLink (Online service)
Other Objects (12)
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen